228 related articles for article (PubMed ID: 24804542)
1. TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.
Fu HL; Ma Y; Lu LG; Hou P; Li BJ; Jin WL; Cui DX
J Biomed Nanotechnol; 2014 Jul; 10(7):1217-30. PubMed ID: 24804542
[TBL] [Abstract][Full Text] [Related]
2. Loss of TET1 facilitates DLD1 colon cancer cell migration via H3K27me3-mediated down-regulation of E-cadherin.
Zhou Z; Zhang HS; Liu Y; Zhang ZG; Du GY; Li H; Yu XY; Huang YH
J Cell Physiol; 2018 Feb; 233(2):1359-1369. PubMed ID: 28513825
[TBL] [Abstract][Full Text] [Related]
3. TET1 inhibits gastric cancer growth and metastasis by PTEN demethylation and re-expression.
Pei YF; Tao R; Li JF; Su LP; Yu BQ; Wu XY; Yan M; Gu QL; Zhu ZG; Liu BY
Oncotarget; 2016 May; 7(21):31322-35. PubMed ID: 27121319
[TBL] [Abstract][Full Text] [Related]
4. Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.
Bai J; Ma M; Cai M; Xu F; Chen J; Wang G; Shuai X; Tao K
Cell Prolif; 2014 Jun; 47(3):211-8. PubMed ID: 24738879
[TBL] [Abstract][Full Text] [Related]
5. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
6. Decrease of 5hmC in gastric cancers is associated with TET1 silencing due to with DNA methylation and bivalent histone marks at TET1 CpG island 3'-shore.
Park JL; Kim HJ; Seo EH; Kwon OH; Lim B; Kim M; Kim SY; Song KS; Kang GH; Kim HJ; Choi BY; Kim YS
Oncotarget; 2015 Nov; 6(35):37647-62. PubMed ID: 26462176
[TBL] [Abstract][Full Text] [Related]
7. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.
Choi JH; Song YS; Yoon JS; Song KW; Lee YY
APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus.
Yamada A; Fujii S; Daiko H; Nishimura M; Chiba T; Ochiai A
Int J Oncol; 2011 Feb; 38(2):345-53. PubMed ID: 21165554
[TBL] [Abstract][Full Text] [Related]
9. Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer.
Du C; Kurabe N; Matsushima Y; Suzuki M; Kahyo T; Ohnishi I; Tanioka F; Tajima S; Goto M; Yamada H; Tao H; Shinmura K; Konno H; Sugimura H
Gastric Cancer; 2015 Jul; 18(3):516-25. PubMed ID: 25098926
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
11. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM; Horlings HM; Hauptmann M; Langerød A; Ajouaou A; Cornelissen-Steijger P; Wessels LF; Jonkers J; van de Vijver MJ; van Lohuizen M
Breast Cancer Res; 2008; 10(6):R109. PubMed ID: 19099573
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of zeste homolog 2 depletion induces cellular senescence via histone demethylation along the INK4/ARF locus.
Jie B; Weilong C; Ming C; Fei X; Xinghua L; Junhua C; Guobin W; Kaixiong T; Xiaoming S
Int J Biochem Cell Biol; 2015 Aug; 65():104-12. PubMed ID: 26004298
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
14. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.
Matsukawa Y; Semba S; Kato H; Ito A; Yanagihara K; Yokozaki H
Cancer Sci; 2006 Jun; 97(6):484-91. PubMed ID: 16734726
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
16. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1.
Liu C; Liu L; Chen X; Shen J; Shan J; Xu Y; Yang Z; Wu L; Xia F; Bie P; Cui Y; Bian XW; Qian C
PLoS One; 2013; 8(5):e62828. PubMed ID: 23671639
[TBL] [Abstract][Full Text] [Related]
17. Activated p53 suppresses the histone methyltransferase EZH2 gene.
Tang X; Milyavsky M; Shats I; Erez N; Goldfinger N; Rotter V
Oncogene; 2004 Jul; 23(34):5759-69. PubMed ID: 15208672
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67 expression patterns in gastric cancer.
Mattioli E; Vogiatzi P; Sun A; Abbadessa G; Angeloni G; D'Ugo D; Trani D; Gaughan JP; Vecchio FM; Cevenini G; Persiani R; Giordano A; Claudio PP
J Cell Physiol; 2007 Jan; 210(1):183-91. PubMed ID: 16998811
[TBL] [Abstract][Full Text] [Related]
19. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer.
Chen DL; Zhang DS; Lu YX; Chen LZ; Zeng ZL; He MM; Wang FH; Li YH; Zhang HZ; Pelicano H; Zhang W; Xu RH
Oncotarget; 2015 May; 6(13):10868-79. PubMed ID: 25869101
[TBL] [Abstract][Full Text] [Related]
20. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
